• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

EMA unveils business continuity plan ahead of UK exit from EU

firstwordpharmaAugust 02, 2017

Tag: EMA , UK , EU

The European Medicines Agency on Tuesday revealed its business continuity plan ahead of its relocation from the UK as part of the country's decision to leave the EU. As part of the initiative, the EMA indicated that it will be reallocating its resources to maintain higher-priority activities over the coming years. EMA's head of the Brexit task force Noel Wathion commented "preparing for the move, managing the necessary changes, and addressing challenges such as possible losses in skilled and experienced staff, in a proactive and efficient way requires considerable internal resources."

Previous:Lonza starts construction of Biological Development and Manufacturing Complex

Next:AbbVie receives EC grant to market HCV treatment Maviret

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

EMA unveils business continuity plan ahead of UK exit from EU | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Terbinafine hydrochloride EP 98%min supplier Pharmaceutical API Broad spectrum Antifungal drugs made

Terbinafine hydrochloride EP 98%min supplier Pharmaceutical API Broad spectrum Antifungal drugs made
(S)-1-(3-Ethoxy-4-Methoxyphenyl)-2-(Methylsulfonyl)ethylaMine N-acetyl-L-leucine salt

(S)-1-(3-Ethoxy-4-Methoxyphenyl)-2-(Methylsulfonyl)ethylaMine N-acetyl-L-leucine salt
GMP Pharmaceutical Medicine 1g Cefotaxime Sodium Injection

GMP Pharmaceutical Medicine 1g Cefotaxime Sodium Injection
Kukoamine A

Kukoamine A
Ellagic acid ≥90.0% supplier API Plant extract Pharmaceutical made in china

Ellagic acid ≥90.0% supplier API Plant extract Pharmaceutical made in china
Cefixime other active pharmaceutical ingredients

Cefixime other active pharmaceutical ingredients
Montelukast sodium

Montelukast sodium
Rosemary oil

Rosemary oil
21-O-Tigloylgymnemagenin

21-O-Tigloylgymnemagenin
2016 Plant Extract Rosemary Essential Oil for Chistmas Promotion

2016 Plant Extract Rosemary Essential Oil for Chistmas Promotion

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service